{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:30:54Z","timestamp":1790951454326,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA041298"],"award-info":[{"award-number":["R01 DA041298"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hepatitis C virus (HCV) treatment can effectively cure HCV among people who inject drugs (PWID). Perspectives of PWID treated in innovative models can reveal program features that address barriers to treatment, and guide implementation of similar models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We interviewed 29 participants in the intervention arm of a randomized trial. The trial enrolled PWID with HCV in New York City from 2017 to 2020 and tested the effectiveness of a low-threshold HCV treatment model at a syringe services program. Participants were purposively sampled and interviewed in English or Spanish. The interview guide focused on prior experiences with HCV testing and treatment, and experiences during the trial. Interviews were inductively coded and analyzed using thematic analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Before enrollment, participants reported being tested for HCV in settings such as prison, drug treatment, and emergency rooms. Treatment was delayed because of not being seen as urgent by providers. Participants reported low self-efficacy, competing priorities, and systemic barriers to treatment such as insurance, waiting lists, and criminal-legal interactions. Stigma was a major factor. Treatment during the trial was facilitated through respect from staff, which overcame stigma. The flexible care model (allowing walk-ins and missed appointments) helped mitigate logistical barriers. The willingness of the staff to address social determinants of health was highly valued.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings highlight the need for low-threshold programs with nonjudgmental behavior from program staff, and flexibility to adapt to participants\u2019 needs. Social determinants of health remain a significant barrier, but programs\u2019 efforts to address these factors can engender trust and facilitate treatment.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> NCT03214679.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-023-00831-9","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T14:03:59Z","timestamp":1690466639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["\u201cTreated like a Human Being\u201d: perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City"],"prefix":"10.1186","volume":"20","author":[{"given":"Shashi N.","family":"Kapadia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesenia","family":"Aponte-Melendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunki","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mateu-Gelabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"831_CR1","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C; 2022. Retrieved January 7, 2022, from https:\/\/www.hcvguidelines.org\/."},{"issue":"9","key":"831_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.7326\/M18-1715","volume":"170","author":"MJ Akiyama","year":"2019","unstructured":"Akiyama MJ, Norton BL, Arnsten JH, Agyemang L, Heo M, Litwin AH. Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial. Ann Intern Med. 2019;170(9):594\u2013603. https:\/\/doi.org\/10.7326\/M18-1715.","journal-title":"Ann Intern Med"},{"key":"831_CR3","doi-asserted-by":"publisher","first-page":"108526","DOI":"10.1016\/j.drugalcdep.2021.108526","volume":"220","author":"SA Assoumou","year":"2021","unstructured":"Assoumou SA, Sian CR, Gebel CM, Linas BP, Samet JH, Bernstein JA. Patients at a drug detoxification center share perspectives on how to increase hepatitis C treatment uptake: a qualitative study. Drug Alcohol Depend. 2021;220:108526. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108526.","journal-title":"Drug Alcohol Depend"},{"key":"831_CR4","doi-asserted-by":"publisher","first-page":"109323","DOI":"10.1016\/j.drugalcdep.2022.109323","volume":"232","author":"CN Behrends","year":"2022","unstructured":"Behrends CN, Lu X, Corry GJ, LaKosky P, Prohaska SM, Glick SN, et al. Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020. Drug Alcohol Depend. 2022;232:109323. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109323.","journal-title":"Drug Alcohol Depend"},{"key":"831_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"198","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80\u20136. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.01.037.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"831_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jhep.2019.10.010","volume":"72","author":"GJ Dore","year":"2020","unstructured":"Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, et al. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J Hepatol. 2020;72(3):431\u201340. https:\/\/doi.org\/10.1016\/j.jhep.2019.10.010.","journal-title":"J Hepatol"},{"issue":"5","key":"831_CR7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1001\/jamainternmed.2022.0170","volume":"182","author":"B Eckhardt","year":"2022","unstructured":"Eckhardt B, Mateu-Gelabert P, Aponte-Melendez Y, Fong C, Kapadia S, Smith M, et al. Accessible hepatitis C care for people who inject drugs: a randomized clinical trial. JAMA Intern Med. 2022;182(5):494\u2013502. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0170.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"831_CR8","doi-asserted-by":"publisher","first-page":"ofy048","DOI":"10.1093\/ofid\/ofy048","volume":"5","author":"BJ Eckhardt","year":"2018","unstructured":"Eckhardt BJ, Scherer M, Winkelstein E, Marks K, Edlin BR. Hepatitis C treatment outcomes for people who inject drugs treated in an accessible care program located at a syringe service program. Open Forum Infect Dis. 2018;5(4):ofy048. https:\/\/doi.org\/10.1093\/ofid\/ofy048.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"831_CR9","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1111\/liv.14634","volume":"40","author":"O Falade-Nwulia","year":"2020","unstructured":"Falade-Nwulia O, Gicquelais RE, Astemborski J, McCormick SD, Kirk G, Sulkowski M, et al. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era. Liver Int. 2020;40(10):2407\u201316. https:\/\/doi.org\/10.1111\/liv.14634.","journal-title":"Liver Int"},{"issue":"11","key":"831_CR10","first-page":"628","volume":"18","author":"A-K Finbr\u00e5ten","year":"2022","unstructured":"Finbr\u00e5ten A-K, Eckhardt BJ, Kapadia SN, Marks KM. Rapid treatment initiation for hepatitis C virus infection: potential benefits, current limitations, and real-world examples. Gastroenterol Hepatol. 2022;18(11):628\u201338.","journal-title":"Gastroenterol Hepatol"},{"key":"831_CR11","doi-asserted-by":"publisher","first-page":"108589","DOI":"10.1016\/j.drugalcdep.2021.108589","volume":"221","author":"C Fong","year":"2021","unstructured":"Fong C, Mateu-Gelabert P, Ciervo C, Eckhardt B, Aponte-Melendez Y, Kapadia S, Marks K. Medical provider stigma experienced by people who use drugs (MPS-PWUD): development and validation of a scale among people who currently inject drugs in New York City. Drug Alcohol Depend. 2021;221:108589. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108589.","journal-title":"Drug Alcohol Depend"},{"key":"831_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.drugpo.2020.102766","volume":"81","author":"T Goodyear","year":"2020","unstructured":"Goodyear T, Ti L, Carrieri P, Small W, Knight R. \u201cEverybody living with a chronic disease is entitled to be cured\u201d: challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs. Int J Drug Policy. 2020;81:102\u2013766. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102766.","journal-title":"Int J Drug Policy"},{"key":"831_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.drugpo.2018.10.004","volume":"62","author":"J Grebely","year":"2018","unstructured":"Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, et al. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. Int J Drug Policy. 2018;62:94\u2013103. https:\/\/doi.org\/10.1016\/j.drugpo.2018.10.004.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"831_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","volume":"3","author":"J Grebely","year":"2018","unstructured":"Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3(3):153\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(17)30404-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"831_CR15","doi-asserted-by":"publisher","first-page":"22146","DOI":"10.7448\/IAS.20.1.22146","volume":"20","author":"J Grebely","year":"2017","unstructured":"Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030\u2014What will it take to get there? J Int AIDS Soc. 2017;20(1):22146. https:\/\/doi.org\/10.7448\/IAS.20.1.22146.","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"831_CR16","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"H-F Hsieh","year":"2005","unstructured":"Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388. https:\/\/doi.org\/10.1177\/1049732305276687.","journal-title":"Qual Health Res"},{"issue":"2","key":"831_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","volume":"14","author":"A Jakubowski","year":"2020","unstructured":"Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med. 2020;14(2):95\u20138. https:\/\/doi.org\/10.1097\/ADM.0000000000000555.","journal-title":"J Addict Med"},{"key":"831_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1477-7517-10-10","volume":"10","author":"AE Jordan","year":"2013","unstructured":"Jordan AE, Masson CL, Mateu-Gelabert P, McKnight C, Pepper N, Bouche K, et al. Perceptions of drug users regarding hepatitis C screening and care: a qualitative study. Harm Reduct J. 2013;10:10. https:\/\/doi.org\/10.1186\/1477-7517-10-10.","journal-title":"Harm Reduct J"},{"issue":"10","key":"831_CR19","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1093\/cid\/cix1062","volume":"66","author":"SN Kapadia","year":"2018","unstructured":"Kapadia SN, Jeng PJ, Schackman BR, Bao Y. State medicaid hepatitis C treatment eligibility criteria and use of direct-acting antivirals. Clin Infect Dis. 2018;66(10):1618\u201320. https:\/\/doi.org\/10.1093\/cid\/cix1062.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"831_CR20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/jvh.13437","volume":"28","author":"SN Kapadia","year":"2021","unstructured":"Kapadia SN, Katzman C, Fong C, Eckhardt BJ, Guarino H, Mateu-Gelabert P. Hepatitis C testing and treatment uptake among young people who use opioids in New York City: a cross-sectional study. J Viral Hepatitis. 2021;28(2):326\u201333. https:\/\/doi.org\/10.1111\/jvh.13437.","journal-title":"J Viral Hepatitis"},{"issue":"12","key":"831_CR21","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/S2468-1253(22)00275-8","volume":"7","author":"AH Litwin","year":"2022","unstructured":"Litwin AH, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, et al. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2022;7(12):1112\u201327. https:\/\/doi.org\/10.1016\/S2468-1253(22)00275-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"831_CR22","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/cid\/ciz976","volume":"71","author":"KN Ly","year":"2020","unstructured":"Ly KN, Mini\u00f1o AM, Liu SJ, Roberts H, Hughes EM, Ward JW, Jiles RB. Deaths associated with hepatitis C virus infection among residents in 50 States and the District of Columbia, 2016\u20132017. Clin Infect Dis. 2020;71(5):1149\u201360. https:\/\/doi.org\/10.1093\/cid\/ciz976.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"831_CR23","doi-asserted-by":"publisher","first-page":"e0207226","DOI":"10.1371\/journal.pone.0207226","volume":"13","author":"A Madden","year":"2018","unstructured":"Madden A, Hopwood M, Neale J, Treloar C. Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PLoS ONE. 2018;13(11):e0207226. https:\/\/doi.org\/10.1371\/journal.pone.0207226.","journal-title":"PLoS ONE"},{"key":"831_CR24","doi-asserted-by":"publisher","first-page":"103165","DOI":"10.1016\/j.drugpo.2021.103165","volume":"96","author":"H Midgard","year":"2021","unstructured":"Midgard H, Ulstein K, Backe \u00d8, Foshaug T, S\u00f8rli H, Vennesland K, et al. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway. Int J Drug Policy. 2021;96:103165. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103165.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"831_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","volume":"17","author":"B Muncan","year":"2020","unstructured":"Muncan B, Walters SM, Ezell J, Ompad DC. \u201cThey look at us like junkies\u201d: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):53. https:\/\/doi.org\/10.1186\/s12954-020-00399-8.","journal-title":"Harm Reduct J"},{"issue":"1","key":"831_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12916-019-1256-2","volume":"17","author":"L Nyblade","year":"2019","unstructured":"Nyblade L, Stockton MA, Giger K, Bond V, Ekstrand ML, Lean RM, et al. Stigma in health facilities: why it matters and how we can change it. BMC Med. 2019;17(1):25. https:\/\/doi.org\/10.1186\/s12916-019-1256-2.","journal-title":"BMC Med"},{"issue":"5","key":"831_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/jvh.13035","volume":"26","author":"J Schulkind","year":"2019","unstructured":"Schulkind J, Stephens B, Ahmad F, Johnston L, Hutchinson S, Thain D, et al. High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. J Viral Hepatitis. 2019;26(5):519\u201328. https:\/\/doi.org\/10.1111\/jvh.13035.","journal-title":"J Viral Hepatitis"},{"key":"831_CR28","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.drugalcdep.2018.06.013","volume":"190","author":"MR Skeer","year":"2018","unstructured":"Skeer MR, Ladin K, Wilkins LE, Landy DM, Stopka TJ. \u201cHep C\u2019s like the common cold\u201d: understanding barriers along the HCV care continuum among young people who inject drugs. Drug Alcohol Depend. 2018;190:246\u201354. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.06.013.","journal-title":"Drug Alcohol Depend"},{"key":"831_CR29","unstructured":"SocioCultural Research Consultants, LLC. Dedoose web application for managing, analyzing, and presenting qualitative and mixed method research data (Version V9.0.46) [Computer software]. SocioCultural Research Consultants, LLC; 2021."},{"issue":"4","key":"831_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","volume":"7","author":"SS Solomon","year":"2022","unstructured":"Solomon SS, Wagner-Cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, et al. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2022;7(4):307\u201317. https:\/\/doi.org\/10.1016\/S2468-1253(21)00397-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"831_CR31","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/14659891.2019.1704076","volume":"25","author":"B Tofighi","year":"2020","unstructured":"Tofighi B, Lee JD, Sindhu SS, Chemi C, Leonard NR. Engagement in the Hepatitis C care continuum among people who use drugs. J Substance Use. 2020;25(4):343\u20139. https:\/\/doi.org\/10.1080\/14659891.2019.1704076.","journal-title":"J Substance Use"},{"issue":"1\u20132","key":"831_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","volume":"131","author":"LC van Boekel","year":"2013","unstructured":"van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1\u20132):23\u201335. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.02.018.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"831_CR33","doi-asserted-by":"publisher","first-page":"e0142770","DOI":"10.1371\/journal.pone.0142770","volume":"10","author":"AJ Wade","year":"2015","unstructured":"Wade AJ, Macdonald DM, Doyle JS, Gordon A, Roberts SK, Thompson AJ, Hellard ME. The cascade of care for an australian community-based hepatitis C treatment service. PLoS ONE. 2015;10(11):e0142770. https:\/\/doi.org\/10.1371\/journal.pone.0142770.","journal-title":"PLoS ONE"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00831-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-023-00831-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00831-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T14:08:40Z","timestamp":1690466920000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-023-00831-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["831"],"URL":"https:\/\/doi.org\/10.1186\/s12954-023-00831-9","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"25 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Drs Kapadia, Eckhardt and Marks report research grants from Gilead Sciences Inc during the conduct of this study. Dr. Aponte-Melendez reports research grants from AbbVie Inc. All other authors report no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}